Veracyte Expands Into Urologic Cancer Testing By Acquiring Decipher For $600M
With the addition of Decipher, Veracyte now offers tests for seven of the 10 most common types of cancer in the US.
With the addition of Decipher, Veracyte now offers tests for seven of the 10 most common types of cancer in the US.